Abstract Details

Title Body Mass Index (BMI) as Predictor of ALSFRS-r Score Decline in ALS Patients

Topic Anterior Horn

Presentation(s) P07 - (-)

Poster/Presentation
Number 085

Objective

Background BACKGROUND: Studies in Amyotrophic Lateral Sclerosis (ALS) patients provide evidence of an association between the ALSFRS-r score and survival. Recent work suggest that BMI predicts ALS patients' survival in a curvilinear manner.

Design/Methods DESIGN/METHODS: We used data from the high dose Coenzyme-Q10 in ALS (QALS) clinical trial, in which patients had in-person ALSFRS-r interviews at baseline and 9 months (n=150). Multiple regression analysis determined whether initial BMI and ALSFRS-r score decline correlate, while adjusting for additional predictors.

Results RESULTS: Preliminary analysis showed that baseline forced vital capacity (FVC) and age, but not study arm, gender, disease site onset, or Riluzole were independently related to ALSFRS-r decline. There was a significant association between initial BMI and ALSFRS-r decline over time only when BMI2 term was added to the model, indicating a curvilinear relationship. In A final multivariate regression model with BMI, BMI2, FVC and age, BMI2 was significantly associated overall with the outcome (p-value=0.02).

Conclusions CONCLUSIONS: There is a significant, curvilinear relationship between initial BMI and ALSFRS-r score decline over time, after adjusting for respiratory function and age.

Authors/Disclosures
PRESENTER	No disclosure on file
Jinsy Andrews, MD, FAAN (Columbia University Medical Center)	Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as a Consultant for Cytokinetics. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as a Consultant for Regeneron. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as a Consultant for Bristol Meyer Squibb. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AL-S Pharma. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Quralis . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Neurosense. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Akava. The institution of Dr. Andrews has received research support from Amylyx. The institution of Dr. Andrews has received research support from Biogen . The institution of Dr. Andrews has received research support from Cytokinetics . The institution of Dr. Andrews has received research support from NIH . The institution of Dr. Andrews has received research support from Prilenia/Platform Trial . The institution of Dr. Andrews has received research support from ALS Platform Trial . The institution of Dr. Andrews has received research support from Corcept.
Dieter Haering	Dieter Haering has received personal compensation for serving as an employee of Novartis.
Richard Buchsbaum	No disclosure on file
	No disclosure on file
Petra Kaufmann, MD, FAAN (Affinia Therapeutics)	Dr. Kaufmann has received personal compensation for serving as an employee of Affinia Therapeutics. Dr. Kaufmann has received personal compensation for serving as an employee of Vigil Neuroscience. Dr. Kaufmann has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for DTx. Dr. Kaufmann has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Taysha Gene Therapies. Dr. Kaufmann has stock in Vigil Neuroscience. The institution of an immediate family member of Dr. Kaufmann has received research support from Cystic Fibrosis Foundation . Dr. Kaufmann has a non-compensated relationship as a Member of a Scientific Advisory Board with NIH that is relevant to AAN interests or activities.
John L. Thompson, PhD (Columbia Univ School of Public Health)	The institution of Dr. Thompson has received research support from NIH.

��ɫ��

��ɫ��